A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 52
- Population
- ALL · 50 Years to 99 Years
- Duration
- 2021-07-13 to 2024-01-31
- Intervention
- Brolucizumab
- Comparator
- Not reported
- Outcomes measured
- Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, We…; Treatment Intervals Before and During the Study — -24 Weeks, Baseline, Week 52; Number of Patients With Prolonged Interval — Baseline, Week 52; Proportion of Patients Who Maintained on q12w Regimen. — Up to week 52; Distribution of Patients at Every 8 Weeks / Every 12 Weeks Intervals - Frequency of Switches in Treatment Intervals Bet…; Mean Change in Best-corrected Visual Acuity — Baseline, Weeks 16 to 28, Week 52; Number of Patients With Best-corrected Visual Acuity Improvements of >= 5, >= 10 and >= 15 Letters — Baseline, up to We…; Number of Patients With Best-corrected Visual Acuity >= 69 Letters — Baseline, up to Week 52; LS Mean Change in Best-corrected Visual Acuity From Baseline at Week 52 — Baseline, Week 52; Change in Central Subfield Thickness From Baseline at Weeks 12, 16, 28 and 52 — Baseline, Weeks 12, 16, 28 and 52; Absence of Intraretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52; Absence of Subretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52; Absence of Sub-retinal Pigment Epithelium Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52; Presence of Active Choroidal Neovascularization Leakage — At Week 52; Overview of TEAEs — Adverse events are reported from first dose of study treatment until end of study treatment plus 30…; Ocular TEAEs in the Study Eye by Primary System Organ Class — Adverse events are reported from first dose of study trea…; Ocular TEAEs in the Study Eye by Preferred Term (at Least 5% in Any Group) — Adverse events are reported from first dos…; Non-ocular TEAEs - Total — Adverse events are reported from first dose of study treatment until end of study treatment…; Ocular TEAEs in the Study Eye of Moderate or Severe Intensity — Adverse events are reported from first dose of study tr…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.